[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "CDC pushes childhood vaccination", "description": "Link for free download of my 2 textbooks in high res PDF\n\nhttp://159.69.48.3/\n\nCOVID-19 Vaccine Recommendations for Children and Teens\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccines-children-teens.html\n\nWhat You Need to Know\n\nCDC recommends everyone ages 5 years and older get vaccinated against COVID-19.\n\nEveryone ages 5 years and older should also get a COVID-19 booster, when eligible.\n\nBooster, at least 5 months after primary course\n\nThe Joint Committee on Vaccination and Immunisation (JCVI)\n\nadvise that all children aged 5 to 11 are offered the coronavirus (COVID-19) vaccine.\n\nhttps://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-covid-19-vaccination-for-children/coronavirus-covid-19-vaccine-for-children-aged-5-to-15/\n\nhttps://www.nhsinform.scot/covid-19-vaccine/the-vaccines/vaccinating-children-aged-5-to-11-years\n\nhttps://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-aged-5-to-11/jcvi-statement-on-vaccination-of-children-aged-5-to-11-years-old\n\nUK, 5 million age 5 to 11\n\nChildren aged 5 to 11 years will be offered 2 doses of the coronavirus vaccine.\n\nJCVI advises a non-urgent offer of two 10 mcg doses of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty\u00ae) to children aged 5 to 11 years of age who are not in a clinical risk group.\n\nWhat about natural immunity\n\nSeroprevalence of Infection-Induced SARS-CoV-2 Antibodies \u2014 United States, September 2021\u2013February 2022\n\nhttps://www.cdc.gov/mmwr/volumes/71/wr/mm7117e3.htm?s_cid=mm7117e3_e&ACSTrackingID=USCDC_921-DM80513&ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2071%2C%20April%2026%2C%202022&deliveryName=USCDC_921-DM80513\n\nanti-N antibodies\n\nAs of February 2022, approximately 75% of children and adolescents had serologic evidence of previous infection with SARS-CoV-2, with approximately one third becoming newly seropositive since December 2021.\n\nThese findings illustrate a high infection rate for the Omicron variant, especially among children\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune\n\nUK, percentage of the population estimated to have antibodies was high for children in Great Britain\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/antibodies\n\nAntibodies against SARS-CoV-2 at or above 179 nanograms per millilitre (ng/ml), UK, 29 November 2021 to 15 May 2022\n\nTesting negative means that an individual did not have enough antibodies to be detected in the test, not that they do not have any immune protection against the virus.\n\nPfizer booster dose, the evidence\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-demonstrating-high-immune\n\nThursday, April 14, 2022\n\nData from a subanalysis of 30 sera\n\nclinical trial of children 5 through 11 years\n\n36-fold increase in SARS-CoV-2 Omicron neutralizing titers following a booster (third) dose\n\nPhase 2/3 clinical trial with 140 children\n\na booster (third) dose increased neutralizing antibodies by 6-fold against the SARS-CoV-2 wild-type strain\n\nCost of Pfizer vaccine for 5 to 11 year olds\n\nhttps://www.pharmaceutical-technology.com/analysis/covid-19-vaccine-pricing-varies-country-company/\n\nEU, $23.15 per dose\n\nUS, $24\n\nUK, x 5,000,000 = $115,750,000\n\nPer primary course, = $231,500,000\n\nWith third dose, $347,250,000\n\n\u00a3289,000,000\n\nUS, x 24,000,000 = $576,000,000\n\nPer primary course, $1,152,000,000\n\nWith third dose, $1,728,000,000\n\nWhy America Doesn't Trust the CDC\n\nhttps://www.newsweek.com/why-america-doesnt-trust-cdc-opinion-1713145\n\nMARTY MAKARY , PROFESSOR, JOHNS HOPKINS SCHOOL OF MEDICINE \n\nCenters for Disease Control (CDC) vigorously recommended the booster for all 5 - 11\n\nPfizer spokesperson, it did not determine the efficacy of the booster in the 5-to-11-year-olds. \n\nAdvisory Committee on Immunization Practices (ACIP).\n\nEleven to one\n\nDr. Keipp Talbot, Vanderbilt University\n\nvaccines, are not without their potential side effects\n\n? sustainability of vaccinating the population every six months\n\nNatural immunity\n\nhttps://www.cdc.gov/mmwr/volumes/71/wr/mm7104e1.htm\n\nCDC data from New York and California demonstrated that natural immunity was 2.8 times more effective in preventing hospitalization \n\n3.3 to 4.7 times more effective in preventing COVID infection compared to vaccination during the Delta wave.", "link": "https://www.youtube.com/watch?v=CjJoc5wqk8E", "date_published": "2022-06-14 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "BA.4 increases with optimism", "description": "(and BA.5) UK, infections increasing\n\nhttps://coronavirus.data.gov.uk/details/healthcare\n\nUptick in Covid hospital admissions in England\n\n33% on the week\n\nIncreases will continue for weeks (2 or 3)\n\nCaused by omicron sub-variants, BA.4 and BA.5\n\nSpreading more readily than BA.2\n\nOffice for National Statistics\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nEarly signs of a possible increase in COVID-19 infections in England and Northern Ireland\n\n \n\nOmicron BA.4 and BA.5, in the ascendancy\n\nTaken over from Omicron BA.2\n\nTaken over from Omicron BA.1\n\nTaken over from Delta\n\nTaken over from Alpha\n\nTaken over from Wuhan original strain\n\nOmicron wave hospital patients\n\n \n\n19% caught the virus in hospital,\n\nhttps://twitter.com/AdeleGroyer/status/1534817326637502464\n\nBA.4 and BA.5 variants emerged in South Africa\n\nBoth evade immunity from vaccination or infection\n\nUK crossover point, (BA.4 and BA.5 over half of cases) Jubilee weekend (2nd to 4th June)\n\nSouth Africa\n\nhttps://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/surveillance-reports/daily-hospital-surveillance-datcov-report/\n\nBA.4 and BA.5 variants had already swept through South Africa, no major problems\n\nDespite multiple reinfections,\n\nDeaths in South Africa were only around a tenth of the peak during previous waves\n\nPrevious immunity has not protected against BA.4 and BA.5 infections\n\nReinfections will increase immunity\n\nSeverity of SARS-CoV-2 Reinfections as Compared with Primary Infections\n\nhttps://www.nejm.org/doi/10.1056/NEJMc2108120\n\nDecember 2021\n\nQatar national cohort of 353,326 \n\nN = 1,304 reinfections\n\nReinfections were rare and were generally mild\n\n(Risk of re-infection, x8 in omicron times compared to delta times)\n\nReinfections had 90% lower odds of resulting in hospitalization or death than primary infections. \n\nUS data\n\nhttps://covid.cdc.gov/covid-data-tracker/#datatracker-home\n\nhttps://covid.cdc.gov/covid-data-tracker/#variant-proportions", "link": "https://www.youtube.com/watch?v=qf8WfAZ8ZUc", "date_published": "2022-06-13 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]